Background-Sustained benefits of drug-eluting stents in femoropopliteal arteries have not been demonstrated. This prospective, multinational, randomized study was designed to compare the 12-month safety and effectiveness of a polymer-free, paclitaxel-coated nitinol drug-eluting stent (DES) with percutaneous transluminal angioplasty (PTA) and provisional bare metal stent (BMS) placement in patients with femoropopliteal peripheral artery disease. Methods and Results-Patients were randomly assigned to primary DES implantation (nϭ236) or PTA (nϭ238).
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specific therapies are limited. Percutaneous transluminal balloon angioplasty (PTA) is associated with unacceptable 1-year restenosis rates (often Ն60%) 1-3 that worsen with lesion complexity. Some first-generation stents were asso-ciated with outcomes similar to PTA. 4, 5 More recently, self-expanding nitinol stents have demonstrated improved patency results, yet restenosis remains a limitation, with 12-month rates between 20% and 37% reported. 3,6 -8 Success in coronary artery intervention 9 -12 led to investigation of drug-eluting stents (DES) in the superficial femoral artery (SFA). Six-month results with polymer-based sirolimuseluting 13 and everolimus-eluting 14 stents were favorable, but benefits were not sustained.
Paclitaxel has been shown to inhibit neointimal hyperplasia, is highly lipophilic, is avidly protein-bound, and partitions into and is retained by arterial tissue. [15] [16] [17] In recent clinical trials, paclitaxel-coated balloons in the SFA have been associated with improved outcomes compared with PTA, 18, 19 further suggesting that prolonged paclitaxel delivery may be unnecessary for inhibiting restenosis.
The purpose of the Zilver PTX Randomized Clinical Study was to evaluate the safety and effectiveness of a selfexpanding nitinol DES with 3 g/mm 2 polymer-free paclitaxel coating on its outer surfaces.
WHAT IS KNOWN
• Restenosis and loss of patency remain limitations of percutaneous transluminal balloon angioplasty (PTA) and bare metal stents (BMS) in the endovascular management of patients with symptomatic femoropopliteal peripheral artery disease. • Data are limited regarding successful use of drugeluting stents (DES) in the treatment of femoropopliteal artery disease.
WHAT THE STUDY ADDS
• The Zilver PTX is a randomized study of a paclitaxel-coated, self-expanding nitinol stent (DES) versus PTA and provisional stenting (BMS versus DES) for lesions up to 14 cm long in the above-theknee femoropopliteal artery. • DES in moderate-length femoropopliteal lesions resulted in superior outcomes at 12 months compared with PTA and BMS, supporting use in this lesion subset. • The results with DES in a broader population of patients with femoropopliteal disease, including lesions longer than 14 cm, could complement the present study.
Methods

Study Design
The Zilver PTX Randomized Clinical Study was a prospective, multinational, controlled trial designed to randomly assign 480 patients with symptomatic PAD involving the above-the-knee femoropopliteal arteries to receive PTA or primary DES (paclitaxelcoated Zilver PTX Drug-Eluting Stent, Cook Medical, Bloomington, IN) treatment. Because PTA often fails acutely, the study included a secondary random assignment to treatment with either the DES or bare metal stent (BMS; Zilver, Cook Medical, Bloomington, IN) immediately after acute PTA failure, providing a direct comparison of the outcome with BMS versus DES in the setting of provisional stenting. To minimize bias, block randomization by site (randomly assigned block sizes of 4 or 6 patients) was performed using an interactive voice response system. Patients with up to 2 de novo or restenotic lesions of the above-the-knee femoropopliteal artery (1 per limb) meeting the general inclusion/exclusion criteria provided written informed consent before the procedure. Major inclusion criteria included Rutherford category Ն2 and resting ankle brachial index (ABI) Ͻ0.9. Major exclusion criteria included untreated Ͼ50% diameter stenosis (DS) of the inflow tract, lesion pretreatment with adjunctive devices, and previous target vessel stenting. Study enrollment occurred only after satisfying the arteriographic inclusion/exclusion criteria, which included lesion length Յ14 cm, Ն50% DS, reference vessel diameter 4 to 9 mm, and at least 1 patent runoff vessel (Ͻ50% DS throughout its course).
The protocol was approved by the US Food and Drug Administration (FDA) under an Investigational Device Exemption, by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), by German authorities, and by the institutional review board or ethics committee at each site. The study was overseen by an independent Data Safety Monitoring Board and was conducted in accordance with Good Clinical Practices. A Clinical Events Committee (CEC) adjudicated major adverse events, and core laboratories provided independent analyses for arteriographic and radiographic imaging (Brigham and Women's Hospital Angiographic Core Laboratory, Boston, MA) and duplex ultrasound imaging (VasCore, Massachusetts General Hospital, Boston, MA).
Interventions
Preprocedure data collection included Rutherford classification, ABI, and Walking Impairment Questionnaire 20 (WIQ; a validated measure of patient-perceived walking performance). After baseline arteriography, eligible patients were randomly assigned to either PTA or DES treatment.
Stents were implanted to fully cover the target lesion(s) and were placed at least 1 cm below the SFA origin and above the medial femoral epicondyle. Predilation and postdilation were at the physician's discretion, with residual DS Ͻ30% required for procedural success.
PTA was performed according to institutional standard practice. Acute PTA failure was defined as Ն30% DS noted on arteriography (including persistent, flow-limiting dissections) or a Ն5 mm Hg mean trans-stenotic pressure gradient. The protocol required 1 repeat, 2-to 3-minute balloon inflation before PTA was considered a failure. Patients who had acute PTA failure underwent secondary random assignment to receive either provisional BMS or DES. PTA treatments that did not acutely fail were considered optimal PTA, and these patients did not receive stents.
Within 3 days after the procedure, all patients underwent ABI assessment and duplex ultrasonography, and high-resolution stent radiographs in 2 planes (1 with the leg straight and 1 with the leg bent 90°at the knee) were obtained for stented patients.
Medical Therapy
The same antiplatelet regimen was recommended for all patients: clopidogrel starting at least 24 hours before the intervention or a procedural loading dose of 300 mg orally; continued clopidogrel therapy for at least 60 days after the procedure; and lifelong aspirin therapy. In Japan, clopidogrel was not available; therefore, ticlopidine was an acceptable substitute.
Follow-Up
Follow-up included telephone contact at 1, 3, and 9 months to assess overall patient condition. The 6-and 12-month in-clinic data collection included ABI, Rutherford score, WIQ, and duplex ultrasound evaluation of patency. High-resolution stent radiographs in 2 planes (1 with the leg straight and 1 with the leg bent 90°at the knee) were also obtained at 12 months to assess stent integrity.
Primary End Points
As required by regulatory authorities, the primary safety and effectiveness hypotheses compared the primary DES and PTA groups. Both analyses were performed per the initial random assignment (ie, intention-to-treat analyses). The primary safety end point was eventfree survival (EFS) at 12 months defined as freedom from both (1) CEC-adjudicated major adverse events (death, amputation, clinically driven target lesion revascularization [TLR], target limb ischemia requiring surgical intervention, or surgical repair of the target vessel) and (2) worsening of the Rutherford score by 2 classes, or to class 5 or 6. Clinically driven TLR was defined as reintervention performed for Ն50% diameter stenosis identified by duplex ultrasound and arteriography within Ϯ5 mm of the target lesion after documentation of recurrent clinical symptoms of PAD.
The primary effectiveness end point was primary patency (including the region 5 mm proximal and distal to the target lesion) at 12 months. Patency was conservatively defined as duplex ultrasoundderived peak systolic velocity ratio Ͻ2.0 from core laboratory analysis or Ͻ50% DS from arteriographic core laboratory analysis, when available. As prespecified, acute PTA failure was counted as a loss of patency for the primary effectiveness end point.
Secondary Evaluations
Protocol-specified secondary evaluations included comparison of the patency rates for provisional DES versus provisional BMS placement after acute PTA failure, comparison of clinical outcomes (ABI, Rutherford score, WIQ) at 12 months for the primary DES versus PTA groups, and stent integrity based on core laboratory analysis of radiographs. Additional evaluations included comparison of patency rates for primary DES versus optimal PTA and primary DES versus PTA with provisional stent placement and assessment of a posttreatment clinical benefit index (defined as freedom from persistent or worsening claudication, rest pain, ulcer, or tissue loss after the initial study treatment).
Statistical Analysis
Sample size was estimated on the basis of available literature describing femoropopliteal PTA outcomes. [21] [22] [23] [24] [25] [26] The calculation assumed the 12-month primary patency rates were 65% and 80% in the PTA and DES groups, respectively. Power analysis was performed using a logistic regression model assumed to contain the treatment effect and 3 binary covariates. 27 The treatment effect was assumed to be the same at each level of the binary covariates. An overall model 2 statistic with 4 degrees of freedom resulted in a sample size of 413 patients, to provide 80% power. Primary patency was assessed using a generalized estimating equations (GEE) model on a per-lesion basis to account for multiple treated lesions per patient. Indepen-dence of multiple lesions was assumed for all lesion analyses, except the primary patency outcome.
The noninferiority primary safety hypothesis was assessed on a per-patient basis using a Z-statistic constructed from the Kaplan-Meier estimates: Zϭ(EFS DES ϪEFS PTA ϩ␦)/SE, where EFS (PTA and DES) are Kaplan-Meier estimates for 12-month EFS rates; ␦ is the minimum difference of practical interest; and SE is the standard error of EFS DES ϪEFS PTA . The power is 0.92, assuming worst-case event-free survival rates (0.50 and 0.55 in the PTA and DES groups, respectively; ␣ϭ0.05, ␦ϭ0.10, and 207 patients per treatment arm).
Analyses were performed using SAS 9.1 (SAS Institute, Cary, NC). The primary methods were Fisher exact test (categorical patient characteristics), unpaired t test (continuous patient characteristics), paired t test (ABI and WIQ), Kaplan-Meier with the log-rank test (time to primary patency) or Z-test (safety), and GEE model (logit for patency and multinomial for Rutherford). The family of probability values for tests of EFS and patency were adjusted for multiplicity. Other probability values are unadjusted.
Results
Between March 2005 and August 2008, 479 patients (238 in the PTA group, and 241 in the DES group) were enrolled at 55 institutions in the United States, Japan, and Germany ( Figure 1 ). Demographics, comorbidities, and lesion characteristics were similar for the groups (Table 1) . These included approximately 91% of patients with claudication (Rutherford classification 2-3) and 9% with critical limb ischemia (Rutherford classification 4 -6), an average lesion length of approximately 65Ϯ40 mm, and approximately 27% total occlusions.
Procedures
Three hundred fifty-nine primary DES were placed (mean, 1.5; median, 1; range, 1-4 stents per patient), with a procedural success rate of 95%. One hundred twenty patients (120/238, 50.4%) in the PTA group had acute PTA failure. After secondary random assignment, 59 and 61 patients with acute PTA failure underwent provisional stent placement, with 93 BMS and 94 DES placed to treat 62 and 63 lesions, respectively. Overall, the most commonly used stent diameters were 6 and 7 mm (91.7%) and the most common length was 80 mm (55.9%).
Safety
The primary DES group exhibited EFS superior to the PTA group (including approximately 50% optimal PTA, 25% provisional BMS, and 25% provisional DES). The 12-month EFS rates were 90.4% for DES and 82.6% for PTA (Pϭ0.004; Figure  2 ), satisfying the primary safety hypothesis.
There were no procedure-or device-related deaths, and amputation and worsening of Rutherford classification were rare, with similar frequencies in the study groups ( Table 2 ). The most common major adverse event was clinically driven TLR. The core laboratory determined arteriographic diameter stenosis immediately before TLR was 80Ϯ16% (meanϮSD), and TLR occurred significantly less often (Pϭ0.01) in the DES group (9.5%; 21/220) than in the PTA group (17.5%; 39/223).
All-cause death (eg, malignancy, pulmonary disease, congestive heart failure) included 4 patients in the PTA group and 9 patients in the DES group (Pϭ0.17). Other reported adverse events were consistent with this patient population and reported at similar rates in both study groups. There were no reports of hypersensitivity reactions or adverse drug effects related to the paclitaxel coating or nitinol stent.
Effectiveness
The 12-month primary patency rate of 83.1% for the primary DES group was significantly superior (PϽ0.001; GEE and log-rank test, Figure 3 ) to the 32.8% for the PTA group (as prespecified, acute PTA failure was counted as a loss of patency), satisfying the primary effectiveness hypothesis.
The secondary comparisons included in Figure 3 also showed superior 12-month primary patency with primary DES placement. Specifically, the 83.1% patency rate for primary DES placement was significantly superior (PϽ0.001) to the 65.3% rate for optimal PTA, a group that excludes patients who had acute PTA failure. In addition, the 83.1% patency rate for primary DES placement was significantly superior (Pϭ0.01) to the 73.4% rate for PTA with provisional stent placement (a group that does not count acute PTA failure as a loss of patency and therefore comprised patients with optimal PTA (50%), and patients with provisional BMS (25%) and provisional DES placement (25%) after acute PTA failure).
The protocol-specified secondary evaluation of the provisional stent groups provided a direct assessment of the paclitaxel effect and showed a superior 12-month primary patency rate of 89.9% for DES compared with 73.0% for BMS (Pϭ0.01; Figure 4 ) in the setting of provisional stenting.
Clinical Outcomes
The ABI values, Rutherford scores, and walking impairment scores each significantly improved (PϽ0.001) from before treatment to 12 months in both the PTA and primary DES groups, with no significant differences between the groups (Table 3) . Additionally, the posttreatment clinical benefit index was sustained through 12 months in 88.3% of patients in the primary DES group, compared with 75.8% of patients in the PTA group (including those who underwent provisional DES and BMS placement after acute PTA failure; PϽ0.001, Figure 5 ). The clinical benefit index was also sustained through 12 months in 90.5% of patients in the provisional DES group, compared with 72.3% in the provisional BMS group (Pϭ0.009, Figure 6 ).
Stent Integrity
There were no periprocedural stent fractures (ie, 529/529 stents were free from fracture after implantation). At 12 months, 453 of 457 (99.1%) DES and BMS were free from fracture, yielding a 12-month fracture rate of 0.9% (4/457). Two fractures each were type I and type III. 28 No fracture was associated with adverse events.
Discussion
Successful endovascular treatment of patients with symptomatic PAD involving the femoropopliteal arteries is challenging, and consensus is lacking regarding the relative effectiveness of various endovascular therapies. The results of the present study met the primary study hypotheses by demonstrating significantly superior 12-month safety (EFS) and effectiveness (primary patency) with the polymer-free paclitaxel-coated DES compared with PTA in symptomatic patients with moderate length (Յ14 cm) SFA and proximal popliteal artery lesions. Specifically, the 12-month primary end point results comparing the PTA and primary DES groups showed EFS rates of 82.6% and 90.4% (Pϭ0.004) and primary patency rates of 32.8% and 83.1% (PϽ0.001), respectively. The patency rate in the DES group was also superior to that of the optimal PTA group, excluding patients who had acute PTA failure (83.1% versus 65.3%; PϽ0.001). These advantages of DES may appear at odds with the secondary clinical outcomes of ABI, Rutherford scores, and walking impairment scores, which all significantly improved (PϽ0.001) from before treatment to 12 months in both the PTA and primary DES groups (with no significant differences between the groups). However, these clinical outcomes include patients who had TLRs, and, importantly, as shown in Table 2 , almost twice as many TLRs were required in the PTA group than the DES group (17.5% versus 9.5%, Pϭ0.01) to achieve these similar clinical outcomes.
The head-to-head randomized comparison of DES versus BMS for provisional stenting after acute PTA failure in 120 patients also showed significantly superior results with DES placement, with primary patency rates of 89.9% and 73.0%, respectively (Pϭ0.01), at 12 months. This represents a greater than 60% reduction in restenosis rate with the paclitaxel-coated DES compared with the BMS.
Previous studies of nitinol BMS in the SFA have shown 12-month patency rates ranging from 63% to 81%, 3 (red and black  curves) . The black curve shows the 32.8% primary patency rate for the percutaneous transluminal angioplasty (PTA) group (as prespecified, acute PTA failure was a loss of patency and accounts for the drop in the PTA patency curve on day 0), and the red curve shows the significantly higher (PϽ0.001) 83.1% primary patency rate for the drug-eluting stent (DES) group. The corresponding life table is included. Secondary evaluations also show that the primary patency rate for the DES (red curve) is (1) significantly higher (PϽ0.001) than the 65.3% primary patency rate for optimal PTA, a group that excludes patients who had acute PTA failure (dotted gray curve), and (2) significantly higher (Pϭ0.01) than the 73.4% primary patency rate for PTA with provisional stent placement, a group that does not count acute PTA failure as a loss of patency and therefore consists of patients with optimal PTA (50%) and those who underwent provisional bare metal stent (BMS) (25%) and provisional DES (25%) placement after acute PTA failure (solid gray curve). and Johnson, Inc, Warren, NJ) coated with sirolimus and a nonresorbable polymer versus identical BMS. The combined SIROCCO restenosis rates by duplex ultrasonography at 18 and 24 months were 18.4% and 22.9%, respectively, for sirolimus-eluting stents and 12.8% and 21.1% for BMS. 13 STRIDES was a single-arm study of 104 patients treated with a nitinol stent coated with everolimus and a nonresorbable polymer (Dynalink-E stent, Abbott Vascular, Inc, Santa Clara, CA). The 12-month patency rate by duplex ultrasonography was 68.5%, dropping to 54.6% at 393 days (the protocol-specified time window for 1-year results). 14 The STRIDES authors compared their results with those with identical BMS (Dynalink) studied in the VIENNA Absolute trial, which demonstrated 63% 12-month patency. 3 It is well known that SFA treatment outcomes are influenced by numerous factors including enrollment criteria, lesion characteristics patency criteria, time window for patency evaluation, and others. Because such factors are likely to vary between studies, cross-study comparisons should be made and interpreted cautiously, and recognized as generally inferior to comparisons made within randomized studies. Differences in SFA DES outcomes are probably also influenced by specific characteristic of the various devices, including stent design, drug and dosage, presence of polymer binders, and kinetics of drug elution and retention at the target lesion. Whereas previous SFA DES used nonresorbable polymers to bind sirolimus or everolimus to the stents, a distinguishing feature of the Zilver PTX stent is the polymerfree paclitaxel coating designed to help avoid the potential inflammatory and thrombotic reactions that may occur with polymers. 29 -31 Since stents were first placed in femoropopliteal arteries, the risk of stent fracture has been a concern. Early experience suggested that stent architecture, length of stented segment, overlapping stents, and extensive, bulky calcified lesions were associated with higher stent fracture rates. In one study, high fracture rates and more severe fractures were associated with increased restenosis rates. 32 Initially published 12-to 18-month fracture rates for a variety of self-expanding nitinol stents range from 12% to 37%, depending on stented length. 6, 13, 32 For moderate-length lesions similar to those in the present study, more recently published 12-month stent fracture rates range from 2.0% to 3.1%. 3, 8 The 12-month fracture rate for the combination of Zilver DES and BMS in this study was 0.9%, further suggesting that contemporary stent designs are more durable and substantially mitigate the fracture risk observed during early SFA stent trials.
Limitations
This study has several potential limitations. FDA policy mandated that the primary randomization of the investigational DES be to PTA because there was not an FDA- ‡Walking scores were obtained from the Walking Impairment Questionnaire, 20 which is a validated measure of patient-perceived walking performance. Patient responses are weighted and the weighted average is reported, with a maximum possible score of 100% in each category.
§Posttreatment clinical benefit was defined as freedom from persistent or worsening claudication, rest pain, ulcer, or tissue loss after the initial study treatment.
ʈPϽ0.001 compared with PTA group; paired t test.
approved, commercially available BMS available for the femoropopliteal arteries at the time of study enrollment. Therefore, the primary study end points compared PTA versus primary DES treatment (and showed significantly superior results with the DES). However, regulatory authorities allowed the study to include a secondary random assignment to treatment with either provisional BMS or DES immediately after acute PTA failure. Importantly, this pre-specified comparison of provisional BMS versus provisional DES treatment also showed significantly superior results with the DES.
Another potential limitation of this study is the high frequency of investigator-determined acute PTA failures (120/238, 50.4%), despite the protocol's rigorous PTA requirements, and the encouragement of investigators to strive for optimal PTA. However, mean trans-stenotic pressure Figure 5 . Twelve-month posttreatment clinical benefit index results for primary drug-eluting stents (DES) compared with percutaneous transluminal angioplasty (PTA) treatment. The clinical benefit index was defined as freedom from persistent or worsening claudication, rest pain, ulcer, or tissue loss after the initial study treatment. The black curve shows that 75.8% of patients in the PTA group maintained clinical benefit; the red curve shows that 88.3% of patients in the primary DES group maintained clinical benefit (PϽ0.001). The corresponding life table is also included. Figure 6 . Twelve-month posttreatment clinical benefit index results for provisional drug-eluting stents (DES) compared with provisional bare metal stent (BMS) treatment. The clinical benefit index was defined as freedom from persistent or worsening claudication, rest pain, ulcer, or tissue loss after the initial study treatment. The black curve shows that 72.3% of patients undergoing provisional BMS placement after acute percutaneous transluminal angioplasty (PTA) failure maintained clinical benefit; the red curve shows that 90.5% of patients undergoing provisional DES placement after acute PTA failure maintained clinical benefit (Pϭ0.009). The corresponding life table is included. gradients Ն5 mm Hg supported 13 of the acute PTA failures, and arteriographic core laboratory measurements showing Ն30% DS confirmed 100 of the acute PTA failures, thereby justifying the investigators' determinations the majority (94.2%) of the time. The frequency of acute PTA failure in similar recent stent studies of moderate length SFA lesions varies from 11% to 40%, complicating the comparative analysis of trial results. 3, 6, 8 Although the study included evaluation of ABI, WIQ, and Rutherford classification, it did not include treadmill exercise testing, which has been used as a functional end point in some other recent SFA trials. 3 However, the posttreatment clinical benefit index (defined as freedom from persistent or worsening claudication, rest pain, ulcer, or tissue loss after the initial study treatment) was included as a secondary clinically based evaluation of patient benefit.
Finally, although the results indicate that the paclitaxelcoated DES delivers superior EFS and patency compared with PTA and provisional BMS placement and support the conclusion that the DES is safe and effective for treatment of patients with moderate length de novo or restenotic lesions of the SFA and proximal popliteal artery, caution should be used when translating these results to treatment of a broader spectrum of femoropopliteal lesions. This is especially important when considering very long segments of disease, which were not included in this trial as per the FDAmandated protocol exclusion of lesions longer than 14 cm.
Conclusion
The Zilver PTX Randomized Clinical Study demonstrated that implantation of a polymer-free, paclitaxel-coated nitinol DES in patients with moderate-length lesions of the SFA and proximal popliteal artery is safe and is associated with superior 12-month patency compared with both PTA and provisional BMS placement.
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